Dr. Eric Verdin

And that's glycan age for whatever reason. Yeah. But the other clocks, frankly, varied between 42 and 67. So the question is, how do we sort through this? And

Well, you picked the best one. So, I mean, there's obviously, there are some significant problems with this. These are not approved clinical tests, but I still think that they have value. And their value really comes back in repetitive measurement, just like you said. So you, you, you, you. First, you need probably to measure many of them.

Well, you picked the best one. So, I mean, there's obviously, there are some significant problems with this. These are not approved clinical tests, but I still think that they have value. And their value really comes back in repetitive measurement, just like you said. So you, you, you, you. First, you need probably to measure many of them.

Well, you picked the best one. So, I mean, there's obviously, there are some significant problems with this. These are not approved clinical tests, but I still think that they have value. And their value really comes back in repetitive measurement, just like you said. So you, you, you, you. First, you need probably to measure many of them.

The paper that you're referring to is a paper in which we did plasmapheresis on a number of patients with a company called Circulate. And we found on a global scale that most of the clocks actually went back when these patients underwent plasmapheresis. But again, there was extreme variation between the different clocks. So I tell people, if you want to use the clocks,

The paper that you're referring to is a paper in which we did plasmapheresis on a number of patients with a company called Circulate. And we found on a global scale that most of the clocks actually went back when these patients underwent plasmapheresis. But again, there was extreme variation between the different clocks. So I tell people, if you want to use the clocks,

The paper that you're referring to is a paper in which we did plasmapheresis on a number of patients with a company called Circulate. And we found on a global scale that most of the clocks actually went back when these patients underwent plasmapheresis. But again, there was extreme variation between the different clocks. So I tell people, if you want to use the clocks,

Companies like True Diagnostic will give you many numbers. They will be all over the place, but the true value comes in looking at how they change over time. Now, the prediction is that over time, We will not only have these epigenetic clocks, we will have proteomics clock, metabolomics clock, facial recognition clocks.

Companies like True Diagnostic will give you many numbers. They will be all over the place, but the true value comes in looking at how they change over time. Now, the prediction is that over time, We will not only have these epigenetic clocks, we will have proteomics clock, metabolomics clock, facial recognition clocks.

Companies like True Diagnostic will give you many numbers. They will be all over the place, but the true value comes in looking at how they change over time. Now, the prediction is that over time, We will not only have these epigenetic clocks, we will have proteomics clock, metabolomics clock, facial recognition clocks.

You know, there's a proliferation of these clocks right now, and they paint a pretty complex picture. And I think they will allow us to do truly preventative medicine. Some of these recent clocks, for example, proteomics clock by Tony Wiskoray at Stanford, are able to measure organ-specific aging.

You know, there's a proliferation of these clocks right now, and they paint a pretty complex picture. And I think they will allow us to do truly preventative medicine. Some of these recent clocks, for example, proteomics clock by Tony Wiskoray at Stanford, are able to measure organ-specific aging.

You know, there's a proliferation of these clocks right now, and they paint a pretty complex picture. And I think they will allow us to do truly preventative medicine. Some of these recent clocks, for example, proteomics clock by Tony Wiskoray at Stanford, are able to measure organ-specific aging.

which is going to be really critical because, of course, as we age, we are always limited by what I call the rate-limiting organ. It could be your liver that's going to fail first, and you would want to know and do an intervention that favors your liver versus your brain versus your heart and so on.

which is going to be really critical because, of course, as we age, we are always limited by what I call the rate-limiting organ. It could be your liver that's going to fail first, and you would want to know and do an intervention that favors your liver versus your brain versus your heart and so on.

which is going to be really critical because, of course, as we age, we are always limited by what I call the rate-limiting organ. It could be your liver that's going to fail first, and you would want to know and do an intervention that favors your liver versus your brain versus your heart and so on.

So I think we're right on the cusp of a revolution in diagnostics, and these epigenetic clocks is the first symptoms going in this direction.

So I think we're right on the cusp of a revolution in diagnostics, and these epigenetic clocks is the first symptoms going in this direction.

So I think we're right on the cusp of a revolution in diagnostics, and these epigenetic clocks is the first symptoms going in this direction.

But interestingly, another anecdote, for example, someone did an interesting experiment where they measured the clocks at different times of the day in the same person. And they found over the 24-hour period, the clock would vary by five years.